{
  "study_id": "NCT00427713",
  "study_title": "Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control",
  "table_name": "Table 1",
  "table_title": "Baseline characteristicsâ€”intention-to-treat population",
  "footnotes": [
    "Note: the apparent imbalance for some of the baseline characteristics (e.g. gender) is due to chance: patients were randomly assigned by blocked stratification using nodal status and surgeon, but with 82 surgeons there were many randomisation 'cells', and with only 113 recruited patients out of the target of 800, this method of randomisation can produce chance imbalances."
  ],
  "groups": [
    {
      "name": "Follow-up only",
      "n": 59
    },
    {
      "name": "Capecitabine + Oxaliplatin",
      "n": 54
    }
  ],
  "characteristics": [
    {
      "original_label": "Age at random assignment (years)",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "numeric_median_iqr",
          "median": 58.0,
          "iqr_min": 52.0,
          "iqr_max": 65.0,
          "raw_string": "58.0 (52.0-65.0)"
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "numeric_median_iqr",
          "median": 59.0,
          "iqr_min": 55.0,
          "iqr_max": 66.0,
          "raw_string": "59.0 (55.0-66.0)"
        }
      ]
    },
    {
      "original_label": "Time from chemotherapy to surgery (weeks)",
      "standardized_name": "Time from chemotherapy to surgery",
      "unit": "weeks",
      "category": "Clinical characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "numeric_median_iqr",
          "median": 9.2,
          "iqr_min": 7.4,
          "iqr_max": 11.4,
          "raw_string": "9.2 (7.4-11.4)"
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "numeric_median_iqr",
          "median": 8.7,
          "iqr_min": 7.1,
          "iqr_max": 11.7,
          "raw_string": "8.7 (7.1-11.7)"
        }
      ]
    },
    {
      "original_label": "Time from radiotherapy to surgery (weeks)",
      "standardized_name": "Time from radiotherapy to surgery",
      "unit": "weeks",
      "category": "Clinical characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "numeric_median_iqr",
          "median": 8.9,
          "iqr_min": 7.1,
          "iqr_max": 10.6,
          "raw_string": "8.9 (7.1-10.6)"
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "numeric_median_iqr",
          "median": 8.5,
          "iqr_min": 7.1,
          "iqr_max": 11.9,
          "raw_string": "8.5 (7.1-11.9)"
        }
      ]
    },
    {
      "original_label": "Time from surgery to randomisation (weeks)",
      "standardized_name": "Time from surgery to randomization",
      "unit": "weeks",
      "category": "Clinical characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "numeric_median_iqr",
          "median": 8.7,
          "iqr_min": 7.3,
          "iqr_max": 10.6,
          "raw_string": "8.7 (7.3-10.6)"
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "numeric_median_iqr",
          "median": 8.9,
          "iqr_min": 7.0,
          "iqr_max": 10.6,
          "raw_string": "8.9 (7.0-10.6)"
        }
      ]
    },
    {
      "original_label": "Gender",
      "standardized_name": "Sex",
      "category": "Demographics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "header",
          "raw_string": "No. (%)"
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "header",
          "raw_string": "No. (%)"
        }
      ]
    },
    {
      "original_label": "Female",
      "standardized_name": "Female",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 20.0,
          "percentage": 33.9,
          "raw_string": "20 (33.9)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 18.5,
          "raw_string": "10 (18.5)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "Male",
      "standardized_name": "Male",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 39.0,
          "percentage": 66.1,
          "raw_string": "39 (66.1)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 44.0,
          "percentage": 81.5,
          "raw_string": "44 (81.5)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "WHO performance status",
      "standardized_name": "WHO performance status",
      "category": "Clinical characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "header",
          "raw_string": "No. (%)"
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "header",
          "raw_string": "No. (%)"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "WHO performance status 0",
      "category": "Clinical characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "WHO performance status",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 37.0,
          "percentage": 62.7,
          "raw_string": "37 (62.7)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 33.0,
          "percentage": 61.1,
          "raw_string": "33 (61.1)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "WHO performance status 1",
      "category": "Clinical characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "WHO performance status",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 22.0,
          "percentage": 37.3,
          "raw_string": "22 (37.3)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 21.0,
          "percentage": 38.9,
          "raw_string": "21 (38.9)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "Tumour site",
      "standardized_name": "Tumor site",
      "category": "Tumor characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "header",
          "raw_string": "No. (%)"
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "header",
          "raw_string": "No. (%)"
        }
      ]
    },
    {
      "original_label": "Lower (0-4.9 cm)",
      "standardized_name": "Lower tumor site (0-4.9 cm)",
      "unit": "cm",
      "category": "Tumor characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor site",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 30.0,
          "percentage": 50.9,
          "raw_string": "30 (50.9)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 46.3,
          "raw_string": "25 (46.3)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "Middle (5-9.9 cm)",
      "standardized_name": "Middle tumor site (5-9.9 cm)",
      "unit": "cm",
      "category": "Tumor characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor site",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 16.0,
          "percentage": 27.1,
          "raw_string": "16 (27.1)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 17.0,
          "percentage": 31.5,
          "raw_string": "17 (31.5)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "Upper (10-15 cm)",
      "standardized_name": "Upper tumor site (10-15 cm)",
      "unit": "cm",
      "category": "Tumor characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor site",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 13.0,
          "percentage": 22.0,
          "raw_string": "13 (22.0)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 22.2,
          "raw_string": "12 (22.2)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "Tumour stage (ypT)",
      "standardized_name": "Tumor stage (ypT)",
      "category": "Tumor characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "header",
          "raw_string": "No. (%)"
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "header",
          "raw_string": "No. (%)"
        }
      ]
    },
    {
      "original_label": "T0",
      "standardized_name": "ypT0",
      "category": "Tumor characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor stage (ypT)",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.7,
          "raw_string": "1 (1.7)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 14.8,
          "raw_string": "8 (14.8)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "T1",
      "standardized_name": "ypT1",
      "category": "Tumor characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor stage (ypT)",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 3.4,
          "raw_string": "2 (3.4)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 3.7,
          "raw_string": "2 (3.7)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "T2",
      "standardized_name": "ypT2",
      "category": "Tumor characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor stage (ypT)",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 14.0,
          "percentage": 23.7,
          "raw_string": "14 (23.7)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 15.0,
          "percentage": 27.8,
          "raw_string": "15 (27.8)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "T3",
      "standardized_name": "ypT3",
      "category": "Tumor characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor stage (ypT)",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 38.0,
          "percentage": 64.4,
          "raw_string": "38 (64.4)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 27.0,
          "percentage": 50.0,
          "raw_string": "27 (50.0)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "T4",
      "standardized_name": "ypT4",
      "category": "Tumor characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Tumor stage (ypT)",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 6.8,
          "raw_string": "4 (6.8)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 3.7,
          "raw_string": "2 (3.7)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "Nodal status (ypN)",
      "standardized_name": "Nodal status (ypN)",
      "category": "Tumor characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "header",
          "raw_string": "No. (%)"
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "header",
          "raw_string": "No. (%)"
        }
      ]
    },
    {
      "original_label": "N0",
      "standardized_name": "ypN0",
      "category": "Tumor characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Nodal status (ypN)",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 31.0,
          "percentage": 52.4,
          "raw_string": "31 (52.4)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 44.0,
          "percentage": 81.5,
          "raw_string": "44 (81.5)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "N1",
      "standardized_name": "ypN1",
      "category": "Tumor characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Nodal status (ypN)",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 23.0,
          "percentage": 39.0,
          "raw_string": "23 (39.0)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 13.0,
          "raw_string": "7 (13.0)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "N2",
      "standardized_name": "ypN2",
      "category": "Tumor characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Nodal status (ypN)",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 8.5,
          "raw_string": "5 (8.5)",
          "n_for_value": 59
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 5.6,
          "raw_string": "3 (5.6)",
          "n_for_value": 54
        }
      ]
    },
    {
      "original_label": "Surgical technique",
      "standardized_name": "Surgical technique",
      "category": "Clinical characteristics",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "header",
          "raw_string": "No. (%)"
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "header",
          "raw_string": "No. (%)"
        }
      ]
    },
    {
      "original_label": "Abdomino-perineal resection",
      "standardized_name": "Abdomino-perineal resection",
      "category": "Clinical characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Surgical technique",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 21.0,
          "percentage": 36.2,
          "raw_string": "21 (36.2)",
          "n_for_value": 58
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 47.2,
          "raw_string": "25 (47.2)",
          "n_for_value": 53
        }
      ]
    },
    {
      "original_label": "Anterior resection",
      "standardized_name": "Anterior resection",
      "category": "Clinical characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Surgical technique",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 31.0,
          "percentage": 53.4,
          "raw_string": "31 (53.4)",
          "n_for_value": 58
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 27.0,
          "percentage": 50.9,
          "raw_string": "27 (50.9)",
          "n_for_value": 53
        }
      ]
    },
    {
      "original_label": "Low Hartmann's",
      "standardized_name": "Low Hartmann's procedure",
      "category": "Clinical characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Surgical technique",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 5.2,
          "raw_string": "3 (5.2)",
          "n_for_value": 58
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 (0.0)",
          "n_for_value": 53
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Other surgical technique",
      "category": "Clinical characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Surgical technique",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 5.2,
          "raw_string": "3 (5.2)",
          "n_for_value": 58
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.9,
          "raw_string": "1 (1.9)",
          "n_for_value": 53
        }
      ]
    },
    {
      "original_label": "Missing",
      "standardized_name": "Missing surgical technique",
      "category": "Clinical characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Surgical technique",
      "group_data": [
        {
          "group_name": "Follow-up only",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "raw_string": "1"
        },
        {
          "group_name": "Capecitabine + Oxaliplatin",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "raw_string": "1"
        }
      ]
    }
  ]
}